All In Biotech

Drug Trial Radar · NCT03675282

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Aug 14, 2018

Primary completion

Apr 23, 2024

Study completion Apr 23, 2024

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Sep 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Prospective, single center study to determine whether the current R2\* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.

Conditions

  • Parkinson Disease
  • REM Sleep Behavior Disorder
  • Healthy

Interventions

  • (11C)PE2IDrug

    Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

  • IoflupaneDrug

    Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR ImagingTime frame: Baseline and 24 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Special Surgery

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.